GnRH analogs for the treatment of symptomatic uterine leiomyomas

Gynecological Surgery

Volumn 2, Issue 1, 2005, Pages 7-13

  Palomba, Stefano ^a,b   Falbo, Angela ^a   Russo, Tiziana ^a   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NONE   (Italy)

Author keywords

Add back therapy; GnRH agonist; GnRH analog; GnRH antagonist; Uterine leiomyomas

Indexed keywords

DANAZOL; GESTAGEN; GESTRINONE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; IPRIFLAVONE; MIFEPRISTONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PIPERAZINE ESTRONE SULFATE; RALOXIFENE; TIBOLONE;

ACNE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSERVATIVE TREATMENT; DRUG EFFICACY; HIRSUTISM; HOT FLUSH; HUMAN; HYPERANDROGENISM; HYSTERECTOMY; LAPAROSCOPIC SURGERY; LAPAROTOMY; LEG CRAMP; LIBIDO DISORDER; MENOPAUSAL SYNDROME; MENORRHAGIA; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OSTEOLYSIS; REVIEW; SEBORRHEA; SIDE EFFECT; TUMOR VOLUME; UTERUS MYOMA; VAGINAL DRYNESS; WEIGHT GAIN;

EID: 18744403979     PISSN: 16132076     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10397-004-0078-0     Document Type: Review

References (75)

1. Steward EA (2001) Uterine fibroids. Lancet 357:293-298
2. Chegini N, Rong H, Dou Q, Kipersztok S, Williams RS (1996) Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 81:3215-3221
3. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P (1998) Sex steroids receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 83:92-96
4. Higashijima T, Kataoka A, Nishida T, Yakushiji M (1996) Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 68:169-173
5. Pasqualini JR, Cornier E, Grenier J, Vella C, Schatz B, Netter A (1990) Effect of decapeptyl, an agonist analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyomata and myometrium. Fertil Steril 53:1012-1017
6. Yamamoto T, Takamori K, Okada H (1984) Estrogen biosynthesis in leiomyomata and myometrium of the uterus. Horm Metab Res 16:678-679
7. Bulun SE, Simpson ER, Word RA (1994) Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissue and cells in culture. J Clin Endocrinol Metab 78:736-743
8. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM (1999) Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 276:1112-1118
9. Rein MS, Barbieri RL, Friedman AJ (1995) Progesterone: A critical role in pathogenesis of uterine myomas. Am J Obstet Gynecol 172:14-18
10. Tiltman AJ (1985) The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4:89-96
11. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T (1989) Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637-641
12. Rein MS (2000) Advanced in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108:791-793
13. Friedman AJ, Thomas PP (1995) Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal with leiomyomas? Obstet Gynecol 85:631-635
14. Barbieri RL (1997) Reduction in the size of a uterine leiomyoma following discontinuation of an estrogen-progestin contraceptive. Gynecol Obstet Invest 43:276-277
15. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz G, Barbieri RL, Stampfer MJ, Hunter DJ (1998) A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 70:432-439
16. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SSC (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76:513-517
17. Kertel LM, Murphy AA, Morales AJ, Yen SS (1994) Clinical Efficacy of antiprogesterone RU 486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 9:116-120
18. Coutinho EM, Goncalves MT (1989) Long-term treatment of leiomyomas with gestrinone. Fertil Steril 51:939-946
19. Coutinho EM (1989) Gestrinone in the treatment of myomas. Acta Obstet Gynecol Scand 150:39-46
20. Coutinho EM (1990) Treatment of large fibroids with high doses of getrinone. Gynecol Obstet Invest 30:44-47
21. De Leo V, La Marca A, Morgante G (1999) Short-term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest 47:258-262
22. De Leo V, La Marca A, Morgante G, Severi FM, Petraglia F (2001) Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Obstet Gynecol 75:632-633
23. Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C (2001) Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 76:38-43
24. Minakuchi K, Kawamura N, Tsujimura A (1999) Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet 353:2127-2128
25. Filicori M, Hall DA, Loughlin JS, Rivier J, Vale W, Crowley WF Jr (1983) A conservative approach to the management of uterine leiomyoma: pituitary desensibilization by a luteinizing hormone-releasing hormone analogue Am J Obstet Gynecol 147:726-727
26. Brosens TA (1997) Variable response of uterine leiomyomas after GnRH agonist therapy. Fertil Steril 68:948-949
27. Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM (1986) Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 63:619-625
28. Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT (1984) Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report. Fertil Steril 42:644-646
29. Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT (1985) Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a study pilot. Am J Obstet Gynecol 152:1034-1038
30. Vollenhoven BJ, Shekleton P, McDonald J, Healy DL (1990) Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women. Fertil Steril 54:1031-1038
31. Palomba S, Zullo F (2001) Leuprolide: as needed? Fertil Steril 76:216-217
32. Zullo F, Pellicano M, Di Carlo C, De Stefano R, Marconi D, Zupi E (1998) Ultrasonographic predictor of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 5:361-366
33. Hackenberg R, Genenhues T, Deiehert U, Duda V, Schmidt-Rhode P, Schulz KD (1992) The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 45:125-129
34. Scialli AR, Levi AJ (2000) Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril 74:540-546
35. Takahashi K, Okada M, Imaoka I, Sugimura K, Miyazaki K (2001) Value of magnetic resonance imaging in predicting efficacy of GnRH analogue treatment for uterine leiomyoma. Hum Reprod 16:1989-1994
36. Aleem FA, Predanic M (1995) The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography. Gynecol Endocrinol 9:253-258
37. Yamamoto H, Sato H, Shibata S, Murata M, Fukuda J, Tanaka T (2001) Involvement of annexin V in the antiproliferative effect of GnRH agonist on cultured human uterine leiomyoma cells. Mol Hum Reprod 7:169-173
38. Rutgers JL, Spong CY, Sinow R, Heiner J (1995) Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 86:386-388
39. Gokdeniz R, Ozen S, Mizrak B, Bazoglu N (2000) GnRH agonist decreases endothelial nitric oxide synthetase (eNOS) expression in leiomyoma. Int J Obstet Gynecol 70:347-352
40. Mizutani T, Sugihara A, Nakamuro K, Terada N (1998) Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 83:1253-1255
41. Pickersgill A (1998) GnRH agonists and add-back therapy: is there a perfect combination ? Br J Obstet Gynaecol 105:475-485
42. Lethaby A, Vollenhoven B, Sowter M (2001) Pre-operative GnRH-analogue therapy before hysterectomy or myomectomy for uterine fibroids. (Cochrane review). In: The Cochrane library, issue 1, Update Software, Oxford
43. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R, Leboff M (1993) A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76:1439-1445
44. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, Leboff M (1994) Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin "add-back" for 2 years. Hum Reprod 9:1618-1625
45. Friedman AJ, Lobel SM, Rein MS, Barbieri RL (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: the estrogen threshold hypothesis. Am J Obstet Gynecol 163:1114-1119
46. Friedman AJ, Barbieri RL, Doublet PM, Fine C, Schiff I (1989) A randomized, double-blind trial of gonadotropin releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 49:404-409
47. Palomba S, Russo T, Orio F jr, Sammartino A, Sbano FM, Nappi C, Colao A, Mastrantonio P, Lombardi G, Zullo F (2004) Lipid, glucose, and homocysteine metabolism in women treated with a gonadotropin-releasing hormone agonist with or without raloxifene. Hum Reprod 19:415-421
48. Carr BR, Marshburn PB, Weatherall PT (1993) An evaluation of the effect of gonadotropin-releasing hormone analog and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double-blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76:1217-1223
49. Nakayama H, Yano T, Sagara Y, Kikuchi A, Ando K, Wang Y, Watanabe M, Matsumi H, Osuga Y, Momoeda M, Taketani Y (1999) Estriol add-back therapy in the long acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Gynecol Endocrinol 13:382-389
50. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16-23
51. Volker W, Coelingh Bennink HJ, Helmond FA (2001) Effects of tibolone on the endometrium. Climacteric 4:203-208
52. Gregoriou O, Vitoratos N, Papadias C, Konidaris S, Costomenos D, Chryssikopoulos A (1997) Effect of tibolone on post-menopausal women with myomas. Maturitas 27:187-191
53. De Aloysio D, Altieri P, Pennacchioni P, Salgarello M, Ventura V (1998) Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 29:261-264
54. Fedele L, Bianchi S, Raffaelli R, Zanconato R (2000) A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 88:91-94
55. Palomba S, Pellicano M, Affinito P, Di Carlo C, Zullo F, Nappi C (2001) Effectiveness of short-term administration of tibolone plus gonadotropin- releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil Steril 75:429-433
56. Palomba S, Affinito P, Tommaselli GA, Nappi C (1998) A clinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 70:111-118
57. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C (1999) Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profile. Fertil Steril 72:889-895
58. Somekawa Y, Chiguchi M, Ishibashi T, Wakana K, Aso T (2001) Efficacy of ipriflavone in preventing adverse effects of leuprolide. J Clin Endocrinol Metab 86:3202-3206
59. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR (1994) Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
60. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C (1996) Inhibition of estrogen stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 17:151-159
61. Bryant HU, Glasebrook AL, Yang NN, Sato M (1996) A pharmacological review of raloxifene. J Bone Miner Metab 14:1-9
62. Porter KB, Tsibris JC, Porter GW, Fuchs-Young R, Nicosia SV, O'Brien WF (1998) Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 179:1283-1287
63. Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R (2000) Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 7:249-256
64. Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Zupi E, Lombardi G, Nappi C, Benedetti Panici PG, Zullo F (2002) Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87:3303-3308
65. Palomba S, Russo T, Orio F Jr, Tauchmananovà L, Zupi E, Benedetti Panici PG, Nappi C, Colao A, Lombardi G, Zullo F (2002) Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 17:3213-3219
66. Palomba S, Orio F jr, Morelli M, Russo T, Pellicano M, Nappi C, Mastrantonio P, Lombardi G, Colao A, Zullo F (2002) Raloxifene administration in women treated with gonadotropin releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 87:4476-4481
67. Palomba S, Orio F jr, Russo T, Falbo A, Amati A, Zullo F (2004) Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life. Fertil Steril (in press)
68. Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Doldo P, Nappi C, Lombardi G, Mastrantonio P, Zullo F (2004) Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 19:1-7
69. Di Carlo C, Palomba S, Tommaselli GA, Guida M, Di Spiezio Sardo A, Nappi C (2001) Use of leuprolide acetate plus tibolone in the treatment of the severe premenstrual syndrome. Fertil Steril 75:380-384
70. Modelska K, Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87:16-23
71. Huirne JA, Lambalk CB (2001) Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793-1803
72. Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS (1993) Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 60:642-646
73. Felberbaum RE, Germer U, Ludwig M, Riethmuller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13:1660-1668
74. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Cornejo IC, Comaru-Schally AV, Engel J, Reissmann T, Riethmuller-Winzen H (1997) Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12:2028-2035
75. Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M (2003) Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J Clin Endocrinol Metab 88:1697-1704